triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host#968257ClinicalTrials.gov
• GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours#981884ClinicalTrials.gov
• Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies#895092ClinicalTrials.gov
• A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy#1029789ClinicalTrials.gov
• a Single-arm, Single-center, Open Clinical Study#916801ClinicalTrials.gov
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors#849329ClinicalTrials.gov
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies#804246ClinicalTrials.gov
• First in Human Study of TUB-030 in Patients With Advanced Solid Tumors#884376ClinicalTrials.gov
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors#123471ClinicalTrials.gov
• A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients#994631ClinicalTrials.gov
• CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)#895495ClinicalTrials.gov
• A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors#807021ClinicalTrials.gov
• A Beta-only IL-2 ImmunoTherapY Study#245502ClinicalTrials.gov
• ERα-Independent Activity of Tamoxifen-Based Transition Metal Hybrids in Triple-Negative Breast Cancer Models In Vitro and In Vivo#241989IBISS
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer#889350ClinicalTrials.gov
• Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.#265381NCBI PubMed Central
• Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation.#438966NCBI PubMed Central
• Genetic association of abcg2 gene polymorphisms with tac chemotherapy response in triple negative breast cancer (TNBC) patients#256578USM Repository
• Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer#283884Figshare
• Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer#283885Figshare
• Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer#283886Figshare
• A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers#838816ClinicalTrials.gov
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors#829476ClinicalTrials.gov
• Structure-guided design and engineering of a biparatopic antibody targeting CCR2 in triple negative breast cancer#233740UNC Dataverse Dataverse OAI Archive
• Boronic Acid-Functionalized MOFs Enable Ultrasensitive Proteomic Profiling of Ultratrace Plasma for Triple-Negative Breast Cancer Diagnosis#370220Figshare
• Epithelial-mesenchymal transition is associated with altered immune composition and cytotoxic function in triple-negative breast cancer#485040Europe PMC
• The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC#806812ClinicalTrials.gov
• Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy#905063ClinicalTrials.gov
• A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors#880988ClinicalTrials.gov
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies#885479ClinicalTrials.gov
• RTX-224 Monotherapy in Patients With Solid Tumors#852137ClinicalTrials.gov
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors#814039ClinicalTrials.gov
• A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs#839634ClinicalTrials.gov
• Phase I/II Study of PDR001 in Patients With Advanced Malignancies#843736ClinicalTrials.gov
• Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2-Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple-Negative Breast Cancer Therapy and Structure-Activity Relationship.#152294NCBI PubMed Central
• Supplementary Material for: Cytokine release syndrome induced by neoadjuvant pembrolizumab in early triple-negative breast cancer: a case report with implications for early diagnosis and management#279901Figshare
• FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors#872147ClinicalTrials.gov
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression#837556ClinicalTrials.gov
• Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial#326123HAL (France)
• Targeting PRMTs Creates Vulnerability of DNA Double‐Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC#442577HAL (France)
• Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC#888572ClinicalTrials.gov
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors#899074ClinicalTrials.gov
• A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer#837059ClinicalTrials.gov
• Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment#906458ClinicalTrials.gov
• A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat#918229ClinicalTrials.gov
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO#141014ClinicalTrials.gov
• MGC018 With or Without MGA012 in Advanced Solid Tumors#1046321ClinicalTrials.gov
• Bidirectional phenotypic transition in macrophages influences triple-negative breast cancer cell immune evasive patterns and response to chemotherapies in a co-culture spheroid model#455604PLOS
• Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC#861766ClinicalTrials.gov
• A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors#1047634ClinicalTrials.gov